Researchers from Northwestern University, along with collaborators at Rice University and Carnegie Mellon University, reported progress toward implantable “living pharmacies” that produce drugs in situ. In rats, the team described a wireless, fully implantable platform (HOBIT) designed to integrate engineered cells with oxygen-generating bioelectronics to sustain cell viability and continuous therapeutic output. The key engineering constraint addressed was oxygen limitation inside dense cell implants, which can otherwise reduce cell survival and shrink drug yield over time. The new iteration embeds localized oxygen generation to maintain production of multiple biologics with more stable in-body delivery. If the approach translates beyond animal models, it could shift chronic disease management from patient-managed dosing to device-controlled, multi-therapy pharmacokinetics.